glp-1 cardiovascular benefits receptor agonists and outcome trials: An update GLP-1 and the cardiovascular system
Description
Klop B, Elte JW, Cabezas MC
writingoriginal draft preparation, E.N
The Court will decide motions for appointment of lead plaintiff and approval of lead counsel in the weeks after submissions are due
Will you receive regular updates
The results demonstrated that the infusion of GLP-1 during high level of glycemia significantly protects endothelial dysfunction and decreases hyperglycemia-induced oxidative stress see Table 2
In the SURMOUT-1 trial 2,539 patients underwent randomization to tirzepatide or placebo and were followed for 72 weeks demonstrating up to 20.9% weight reduction with maintenance dosing versus 3.1% in the placebo group for a net 17.8% weight reduction [35]
